Methods for analyzing viral capsid protein composition
Hydrophilic interaction liquid chromatography (HILIC) is used to precisely characterize AAV particle homogeneity by separating and quantifying capsid proteins, addressing the challenge of insufficient resolution in existing methods and ensuring the quality of gene therapy vectors.
Patent Information
- Application Number
- JP2022174334
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-10-25
- Filing Date
- 2022-10-31
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2039-10-24
AI Technical Summary
Current methods for characterizing viral particle homogeneity, particularly for adeno-associated virus (AAV) vectors used in gene therapy, lack sufficient resolution and accuracy in quantifying uniformity and structural protein composition, which is crucial for ensuring product quality and consistency.
A method utilizing hydrophilic interaction liquid chromatography (HILIC) to separate and determine the mass of viral capsid proteins, such as VP1, VP2, and VP3, and comparing these masses to theoretical values to assess stoichiometry and heterogeneity, allowing for precise characterization of AAV particles.
Provides high-resolution separation and quantification of viral capsid proteins, enabling accurate determination of AAV particle homogeneity and ensuring the quality and consistency of gene therapy vectors.
Smart Images

Figure 0007577719000003 
Figure 0007577719000004 
Figure 0007577719000005
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 62 / 750,583, filed October 25, 2018, which is incorporated by reference in its entirety for all purposes.
[0002] FIELD OF THEINVENTION The present invention relates to a method for determining the heterogeneity of viral particles, such as adeno-associated viral (AAV) particles, using hydrophilic interaction liquid chromatography (HILIC) and mass spectrometry. [Background technology]
[0003] Gene therapy has gained attention as an alternative treatment for genetic diseases. Gene therapy involves the introduction of some genetic material (DNA, RNA or oligonucleotides) into the target cells. In practice, the gene of interest (also called transgene) needs to be delivered to the cells by a vector carrying a molecule of DNA or RNA. Gene therapy is based on the introduction of a functional gene that replaces or supplements a defective gene. The transgene can be delivered to the cells by a vector. The method of delivery varies depending on the type of treatment and the organ / tissue to be targeted.
[0004] Viral particles are known as vectors for gene therapy and disease treatment. Viral vectors, such as those based on the adeno-associated virus (AAV) genome, are promising platforms for gene delivery. Currently, 12 human serotypes of AAV (AAV1-12) have been described, many of which have distinct cell and tissue tropisms, potentially giving rise to a wide variety of vector classes from this viral genus.
[0005] However, one of the problems faced when adopting viral vectors for gene therapy is the characterization of viral particle homogeneity. Although classical techniques such as electron microscopy and Southern blot can characterize viral particle heterogeneity such as AAV heterogeneity and aggregation, they do not provide sufficient resolution to quantify homogeneity when it comes to producing clinical grade viral vector preparations. To ensure product quality and consistency, complete characterization of structural viral capsid proteins such as the capsid protein of AAV vectors, including sequence and post-translational modifications (PTMs), is highly recommended. Therefore, a method to determine viral particle homogeneity is needed. Summary of the Invention
[0006] In one aspect, the present invention provides a method for determining the stoichiometry of protein components of a viral capsid of a viral particle, the method comprising: (a) subjecting a sample of viral particles to hydrophilic interaction liquid chromatography (HILIC) to separate protein components of the viral capsid of the viral particle; (b) determining masses of the viral capsid protein components to identify the protein components separated by HILIC; and (c) determining relative abundances of the viral capsid protein components from the HILIC separation, thereby determining the stoichiometry of the protein components of the viral capsid of the viral particle.
[0007] In another aspect, the present invention provides a method for determining protein heterogeneity in a capsid of a virus particle, the method comprising: (a) subjecting the virus particle to HILIC to separate protein components of the virus particle capsid; (b) determining masses of the protein components of the protein capsid; and (c) comparing the determined masses of the protein components of the virus particle capsid with theoretical masses, wherein deviations in one or more of the masses of the protein components of the virus particle capsid from the theoretical mass are indicative of capsid heterogeneity.
[0008] In some embodiments, the viral particle comprises an adeno-associated viral (AAV) particle.
[0009] In some embodiments, the protein components of the viral capsid include VP1, VP2, and VP3 of the AAV particle.
[0010] In some embodiments, the heterogeneity comprises one or more of a mix of serotypes, variant capsids, substitutions of capsid amino acids, truncated capsids, or modified capsids.
[0011] In some embodiments, the AAV particle comprises an AAV1 capsid, an AAV2 capsid, an AAV3 capsid, an AAV4 capsid, an AAV5 capsid, an AAV6 capsid, an AAV7 capsid, an AAV8 capsid, an AAVrh8 capsid, an AAV9 capsid, an AAV10 capsid, an AAV11 capsid, an AAV12 capsid, or a variant thereof.
[0012] In some embodiments, the masses of VP1, VP2, and VP3 are compared to the theoretical masses of one or more of an AAV1 capsid, an AAV2 capsid, an AAV3 capsid, an AAV4 capsid, an AAV5 capsid, an AAV6 capsid, an AAV7 capsid, an AAV8 capsid, an AAVrh8 capsid, an AAV9 capsid, an AAV10 capsid, an AAV11 capsid, an AAV12 capsid, or a variant thereof.
[0013] In some embodiments, the AAV particle comprises an AAV1 inverted terminal repeat (ITR), an AAV2 ITR, an AAV3 ITR, an AAV4 ITR, an AAV5 ITR, an AAV6 ITR, an AAV7 ITR, an AAV8 ITR, an AAVrh8 ITR, an AAV9 ITR, an AAV10 ITR, an AAVrh10 ITR, an AAV11 ITR, or an AAV12 ITR.
[0014] In some embodiments, the AAV particles have a capsid serotype selected for transducing cells of the subject's liver.
[0015] In some embodiments, the AAV particles are recombinant AAV (rAAV) particles.
[0016] In some embodiments, the AAV particle comprises an AAV vector encoding a heterologous transgene.
[0017] In some embodiments, the AAV particles have capsid serotypes AAV7, AAV8, or AAV9.
[0018] In some embodiments, the AAV particles have capsid serotype AAV9.
[0019] In some embodiments, the AAV particle is a viral vector having the capsid serotype AAV9 and encoding lysosomal alpha glucosidase (GAA) linked to an anti-CD63 antibody.
[0020] In some embodiments, the viral particle comprises a viral vector encoding a heterologous transgene.
[0021] In some embodiments, the viral particle belongs to a virus family selected from the group consisting of Adenoviridae, Parvoviridae, Retroviridae, Baculoviridae, and Herpesviridae.
[0022] In some embodiments, the viral particle belongs to a viral genus selected from the group consisting of atadenovirus, aviadenovirus, ictadenovirus, mastadenovirus, siaadenovirus, ambidensovirus, brevidensovirus, hepandensovirus, iteradensovirus, penstildensovirus, amdoparvovirus, abeparvovirus, bocaparvovirus, copiparvovirus, dependoparvovirus, erythroparvovirus, protoparvovirus, tetraparvovirus, alpharetrovirus, betaretrovirus, deltaretrovirus, epsilonretrovirus, gammaretrovirus, lentivirus, spumavirus, alphabaculovirus, betabaculovirus, deltabaculovirus, gammabaculovirus, irtovirus, mardivirus, simplexvirus, varicellovirus, cytomegalovirus, muromegalovirus, proboscivirus, roseolovirus, lymphocryptovirus, macavirus, percavirus, and rhadinovirus.
[0023] In some embodiments, the retrovirus is Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), mouse mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend virus, murine stem cell virus (MSCV), Rous sarcoma virus (RSV), human T-cell leukemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), equine immunodeficiency virus (EIV), Visna-Maedi virus; caprine arthritis-encephalitis virus; equine infectious anemia virus; feline immunodeficiency virus (FIV); bovine immunodeficiency virus (BIV); or simian immunodeficiency virus (SIV).
[0024] In some embodiments, HILIC uses a mobile phase A that comprises trifluoroacetic acid in water.
[0025] In some embodiments, mobile phase A contains about 0.1% trifluoroacetic acid.
[0026] In some embodiments, the chromatography comprises a mobile phase B comprising trifluoroacetic acid in acetonitrile.
[0027] In some embodiments, mobile phase B contains about 0.1% trifluoroacetic acid.
[0028] In some embodiments, the proportion of mobile phase A in the chromatography is increased over time.
[0029] In some embodiments, mobile phase A is increased from about 15% to about 100% over about 45 minutes. [The present invention 1001] 1. A method for determining the stoichiometry of protein components of a viral capsid of a viral particle, comprising: subjecting a sample of the viral particles to hydrophilic interaction liquid chromatography (HILIC) to separate protein components of the viral capsid of said viral particles; determining the masses of protein components of the viral capsid to identify the protein components separated by HILIC; determining the relative abundance of the viral capsid protein components from the HILIC separation, thereby determining the stoichiometry of the viral capsid protein components of the viral particle; The method comprising: [The present invention 1002] The method of claim 10, wherein the viral particles comprise adeno-associated viral (AAV) particles. [The present invention 1003] The method of claim 1002, wherein the protein components of the protein capsid include VP1, VP2 and VP3 of the AAV particle. [The present invention 1004] The method of claim 1002, wherein the masses of VP1, VP2, and VP3 are compared to the theoretical masses of one or more of an AAV1 capsid, an AAV2 capsid, an AAV3 capsid, an AAV4 capsid, an AAV5 capsid, an AAV6 capsid, an AAV7 capsid, an AAV8 capsid, an AAVrh8 capsid, an AAV9 capsid, an AAV10 capsid, an AAV11 capsid, an AAV12 capsid, or a variant thereof. [The present invention 1005] The method of claim 1003, wherein the AAV particle comprises an AAV1 capsid, an AAV2 capsid, an AAV3 capsid, an AAV4 capsid, an AAV5 capsid, an AAV6 capsid, an AAV7 capsid, an AAV8 capsid, an AAVrh8 capsid, an AAV9 capsid, an AAV10 capsid, an AAV11 capsid, an AAV12 capsid, or a variant thereof. [The present invention 1006] The method of claim 1002, wherein the AAV particle comprises an AAV1 ITR, an AAV2 ITR, an AAV3 ITR, an AAV4 ITR, an AAV5 ITR, an AAV6 ITR, an AAV7 ITR, an AAV8 ITR, an AAV9 ITR, an AAV10 ITR, an AAV11 ITR, or an AAV12 ITR. [The present invention 1007] The method of claim 1002, wherein said AAV particle is a recombinant AAV (rAAV) particle or an AAV vector encoding a heterologous transgene. [The present invention 1008] The method of claim 1002, wherein the AAV particles have a capsid serotype selected for transducing cells of the subject's liver. [The present invention 1009] The method of claim 1008, wherein the AAV particles have capsid serotype AAV7, AAV8, or AAV9. [The present invention 1010] The method of claim 1009, wherein the AAV particles have capsid serotype AAV9. [The present invention 1011] The method of claim 1002, wherein the AAV particle is a viral vector having the capsid serotype AAV9 and encoding lysosomal alpha glucosidase (GAA) linked to an anti-CD63 antibody. [The present invention 1012] The method of the present invention 1001, wherein the viral particle comprises a viral vector encoding a heterologous transgene or belongs to a virus family selected from the group consisting of Adenoviridae, Parvoviridae, Retroviridae, Baculoviridae, and Herpesviridae. [The present invention 1013] The method of the present invention, wherein the viral particle belongs to a virus genus selected from the group consisting of atadenovirus, aviadenovirus, ictadenovirus, mastadenovirus, siaadenovirus, ambidensovirus, brevidensovirus, hepandensovirus, iteradensovirus, penstildensovirus, amdoparvovirus, abeparvovirus, bocaparvovirus, copiparvovirus, dependoparvovirus, erythroparvovirus, protoparvovirus, tetraparvovirus, alpharetrovirus, betaretrovirus, deltaretrovirus, epsilonretrovirus, gammaretrovirus, lentivirus, spumavirus, alphabaculovirus, betabaculovirus, deltabaculovirus, gammabaculovirus, irtovirus, mardivirus, simplexvirus, varicellovirus, cytomegalovirus, muromegalovirus, proboscivirus, roseolovirus, lymphocryptovirus, macavirus, percavirus, and rhadinovirus. [The present invention 1014] The method of the present invention, wherein the retrovirus is Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), mouse mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend virus, murine stem cell virus (MSCV), Rous sarcoma virus (RSV), human T-cell leukemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), equine immunodeficiency virus (EIV), Visna-Maedi virus; Caprine arthritis-encephalitis virus; Equine infectious anemia virus; Feline immunodeficiency virus (FIV); Bovine immunodeficiency virus (BIV); or Simian immunodeficiency virus (SIV). [The present invention 1015] 1001. The method of claim 1001, wherein said HILIC uses a mobile phase A comprising trifluoroacetic acid in water or a mobile phase B comprising trifluoroacetic acid in acetonitrile. [The present invention 1016] The method of claim 1013, wherein said mobile phase A or said mobile phase B comprises about 0.1% trifluoroacetic acid. [The present invention 1017] The method of claim 1015, wherein the proportion of mobile phase A in the chromatography is increased over time. [The present invention 1018] The method of claim 1017, wherein mobile phase A is increased from about 15% to about 100% over about 45 minutes. [The present invention 1019] 1. A method for determining the heterogeneity of protein components in a capsid of a viral particle, comprising: subjecting the viral particles to hydrophilic interaction liquid chromatography (HILIC) to separate protein components of the viral particle capsid; determining the mass of the protein components of said protein capsid; comparing the determined masses of protein components of the virus particle capsid with theoretical masses, wherein deviations of one or more of the masses of protein components of the virus particle capsid from the theoretical mass indicate capsid heterogeneity; The method comprising: [The present invention 1020] The method of claim 1019, wherein said heterogeneity comprises one or more of a mixture of serotypes, variant capsids, substitutions of capsid amino acids, truncated capsids, or modified capsids. [Brief description of the drawings]
[0030] [Figure 1] Schematic model of a possible treatment regimen for Pompe disease, including the use of adeno-associated virus (AAV) as a gene therapy vector. [Diagram 2] Figure 2A is a model of the AAV viral capsid, and Figure 2B is a schematic representation of the viral capsid proteins of AAV serotypes and their approximate masses. [Figure 3A] UV trace of reversed-phase TIC separation of AAV capsid proteins from AAV particles, showing poor resolution of individual proteins. [Figure 3B] A comparison of several prior art separation methods, showing both poor resolution and / or poor quantification. [Figure 4] FIG. 2 is a UV trace of hydrophilic interaction liquid chromatography (HILIC) separation of AAV capsid proteins from AAV particles, showing high resolution of individual proteins and determination of the relative abundance of individual proteins. [Figure 5A] Mass spectrum of AAV capsid protein from AAV particles. [Figure 5B] Mass spectrum of AAV capsid protein from AAV particles. [Figure 5C] Mass spectrum of AAV capsid protein from AAV particles. [Figure 5D] Mass spectrum of AAV capsid protein from AAV particles. [Figure 6] Shown are two traces of HILIC-UV analysis of AAV9 viral particles and determination of their stoichiometry. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] Detailed Description of the Invention Before describing the present invention, it is understood that the present invention is not limited to the specific methods and experimental conditions described, as such methods and conditions can vary. It is also understood that the terminology used herein is for the purpose of describing specific embodiments only, and is not intended to be limiting, since the scope of the present invention is limited only by the appended claims. Any of the embodiments or features of the embodiments can be combined with each other, and such combinations are expressly encompassed within the scope of the present invention.
[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs.As used herein, the term "about" when used in relation to a specific recited numerical value means that the value may vary from the recited value by no more than 1%.For example, as used herein, the expression "about 100" includes 99 and 101, and all values therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0033] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below. All patents, applications, and non-patent publications mentioned herein are incorporated by reference in their entirety.
[0034] Abbreviations used herein MS / MS: Tandem mass spectrometry MS: Mass spectrometry ITR: inverted terminal repeat rAAV vector: recombinant AAV vector HILIC: Hydrophilic Interaction Liquid Chromatography GAA: Lysosomal alpha-glucosidase mAb: Monoclonal antibody IgG: immunoglobulin G LC: light chain HC: Heavy chain AAV: adeno-associated virus PTM: Post-translational modification ERT: Enzyme replacement therapy
[0035] definition "Adeno-associated virus" or "AAV": AAV is a non-pathogenic parvovirus with a single-stranded DNA genome of approximately 4.7 kb and a non-enveloped icosahedral structure. AAV was originally discovered in 1965 as a contaminant in adenovirus preparations. AAV belongs to the genus Dependovirus and family Parvoviridae because it requires helper functions from either herpesvirus or adenovirus for its replication. In the absence of helper virus, AAV can enter a latent state by integrating into human chromosome 19 at location 19q13.4. The AAV genome consists of two open reading frames (ORFs) for each of the two AAV genes, Rep and Cap. The DNA termini of AAV have 145-base terminal inverted repeats (ITRs), with the terminal 125 bases palindromic, resulting in a characteristic T-shaped hairpin structure.
[0036] The Rep gene is transcribed from promoters p5 and p19 into four Rep proteins (Rep78, Rep68, Rep52, and Rep40), which play important roles in the viral life cycle. Proteins Rep78 and Rep68 are encoded by mRNA transcribed from promoter p5. These proteins are necessary for the control of viral DNA replication, transcription, and site-specific integration. Two smaller proteins, Rep52 and Rep40, are generated by mRNA transcribed from promoter p19. These proteins are involved in the formation of a single-stranded viral genome for packaging and viral integration. The Cap gene encodes three viral capsid proteins: VP1 (735 amino acids, approximately 90 kDa), VP2 (598 amino acids, approximately 72 kDa), and VP3 (533 amino acids, approximately 60 kDa), which form the 60-subunit viral capsid in a ratio of 1:1:10 (see Figures 2A and 2B). The three capsid proteins are translated from an mRNA transcribed from the promoter p40.
[0037] The term "antibody", as used herein, is intended to refer to an immunoglobulin molecule (i.e., an "intact antibody molecule") composed of four polypeptide chains, two heavy (H) and two light (L) chains interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM) or antigen-binding fragments thereof. Each heavy chain contains a heavy chain variable region ("HCVR" or "V H ") and the heavy chain constant region (domain C H 1. C H 2 and C H In various embodiments, the heavy chain may be of the IgG isotype. In some cases, the heavy chain is selected from IgG1, IgG2, IgG3, or IgG4. In some embodiments, the heavy chain is of isotype IgG1 or IgG4, and optionally includes a chimeric hinge region of isotype IgG1 / IgG2 or IgG4 / IgG2. Each light chain is composed of a light chain variable region ("LCVR" or "VVR"). L ) and light chain constant region (CL ) is composed of V H Area and V L The region can be further divided into regions of hypervariability called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). H and V L is composed of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The term "antibody" includes reference to both glycosylated and non-glycosylated immunoglobulins of any isotype or subclass. The term "antibody" includes antibody molecules prepared, expressed, produced or isolated by recombinant means, e.g., antibodies isolated from a host cell transfected to express the antibody. For reviews on antibody structure, see Lefranc et al., IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains, 27(1) Dev. Comp. Immunol. 55-77 (2003); and M. Potter, Structural correlates of immunoglobulin diversity, 2(1) Surv. Immunol. Res. 27-42 (1983).
[0038] The term antibody also encompasses "bispecific antibodies," which include heterotetrameric immunoglobulins that can bind to more than one different epitope. One half of a bispecific antibody, which contains a single heavy chain and a single light chain and six CDRs, binds one antigen or epitope, and the other half of the antibody binds a different antigen or epitope. In some cases, bispecific antibodies can bind to the same antigen but different or non-overlapping epitopes. In some cases, both halves of a bispecific antibody have the same light chain, while retaining the bispecificity. Bispecific antibodies are reviewed in U.S. Patent Application Publication No. 2010 / 0331527 (December 30, 2010).
[0039] The terms "antigen-binding portion" and "antigen-binding fragment" of an antibody (or "antibody fragment") refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. Examples of binding fragments encompassed by the term "antigen-binding portion" of an antibody include (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')2 fragment, which is a bivalent fragment containing two Fab fragments linked by a disulfide bridge at the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment consisting of the VH domain (Ward et al. (1989) Nature 241:544-546); (vi) an isolated CDR; and (vii) an scFv consisting of the two domains, VL and VH, of the Fv fragment connected by a synthetic linker, where the pair of the VL and VH domains forms a monovalent molecule to form a single protein chain. Other forms of single chain antibodies, such as diabodies, are also encompassed by the term "antibody" (see, e.g., Holliger et al. (1993) 90 PNAS USA 6444-6448; and Poljak et al. (1994) 2 Structure 1121-1123).
[0040] Furthermore, antibodies and antigen-binding fragments thereof can be obtained using standard recombinant DNA techniques generally known in the art (see Sambrook et al., 1989).
[0041] The term "human antibody" is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human mAbs of the invention may contain amino acid residues (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo) not encoded by human germline immunoglobulin sequences, for example in the CDRs and in particular the CDR3. However, the term "human antibody" as used herein is not intended to include mAbs in which CDR sequences derived from the germline of another mammalian species (e.g., mouse) have been grafted onto human FR sequences. This term includes antibodies recombinantly produced in non-human mammals or in cells of non-human mammals. This term is not intended to include antibodies isolated from or generated in a human subject.
[0042] The term "corresponding" is a relative term indicating similarity in location, purpose or structure. A mass spectral signal attributable to a particular peptide or protein is also referred to as the signal corresponding to that peptide or protein. In certain embodiments, a particular peptide sequence or set of amino acids, such as a protein, can be assigned to a corresponding peptide mass.
[0043] The term "isolated," as used herein, refers to a biological component (such as a nucleic acid, peptide, protein, lipid, viral particle, or metabolite) that is substantially separated from, produced away from, or purified from other biological components within the cells of an organism in which it naturally occurs or is transgenically expressed.
[0044] "Mass spectrometry" is a method of analyzing a sample by generating gas phase ions from the sample, which are then separated and detected according to their mass to charge ratio (m / z). Methods of generating gas phase ions from a sample include electrospray ionization (ESI), matrix-assisted laser desorption ionization (MALDI), surface-enhanced laser desorption ionization (SELDI), chemical ionization, and electron impact ionization (EI). Separation of ions according to their m / z ratio can be performed in any type of mass spectrometer, including quadrupole mass spectrometers (Q), time-of-flight (TOF) mass spectrometers, magnetic sector mass spectrometers, 3D and linear ion traps (IT), orbitrap mass spectrometers, Fourier transform ion cyclotron resonance (FT-ICR) spectrometers, and combinations thereof (e.g., quadrupole time-of-flight spectrometers, or Q-TOF spectrometers). The sample may be subjected to one or more chromatographic separations, such as HILIC, prior to separation.
[0045] Tandem mass spectrometry, or MS / MS, is a technique that breaks down selected ions (precursor ions) into fragments (product ions) that then reveal aspects of the precursor ion's chemical structure. In tandem mass spectrometry, once a sample is ionized (e.g., by ESI, MALDI, EI, etc.) to produce a mixture of ions, a precursor ion of a particular mass-to-charge ratio (m / z), e.g., a peptide from a digest, is selected (MS1) and then fragmented (MS2) to produce product ions for detection. Typical tandem MS instruments include QqQ, QTOF, and hybrid ion trap / FTMS. One application of tandem mass spectrometry is protein identification. The first mass analyzer isolates ions of a particular m / z value representing a single peptide species from the many ions introduced into and emerging from the ion source. These ions are then accelerated into a collision cell filled with an inert gas, such as argon, to induce ion fragmentation. This process is called collision-induced dissociation (CID) or collision-activated dissociation (CAD). The m / z values of the fragment ions are then measured in a second mass spectrometer to obtain amino acid sequence information. According to the methods disclosed herein, tandem mass spectrometry can be used to identify the sequence of a peptide, and thus the sequence of a full-length or partial-length protein. Precursor ions can be activated (with an increase in internal energy) in a number of different ways. The fragmentation pattern depends on how energy is transferred to the precursor ion, the amount of energy transferred, and how the transferred energy is distributed internally. Collision-induced dissociation and infrared multiphoton dissociation are "slow heating" techniques that preferentially break the weakest bonds by increasing the Boltzmann temperature of the ion.
[0046] The terms "peptide", "protein" and "polypeptide" refer interchangeably to a polymer of amino acids and / or amino acid analogs joined by peptide bonds or peptide bond mimetics. The 20 naturally occurring amino acids and their one-letter and three-letter abbreviations are: A Ala for alanine, C Cys for cysteine, D Asp for aspartic acid, E Glu for glutamic acid, F Phe for phenylalanine, G Gly for glycine, H His for histidine, I He for isoleucine, K Lys for lysine, L Leu for leucine, M Met for methionine, N Asn for asparagine, P Pro for proline, Q Gln for glutamine, R Arg for arginine, S Ser for serine, T Thr for threonine, V Val for valine, w Trp for tryptophan and Y Tyr for tyrosine.
[0047] Reference to the mass of an amino acid refers to the monoisotopic mass or average mass of the amino acid at a given isotopic abundance, such as natural abundance.In some instances, the mass of an amino acid can be biased, for example, by labeling the amino acid with an isotopically.For each single amino acid, some variation is expected around the average mass of the amino acid, based on the exact isotopic composition of the amino acid.The mass of an amino acid, including the monoisotopic mass and the average mass, can be easily obtained by those skilled in the art.
[0048] Similarly, the mass of a peptide or protein refers to the monoisotopic mass or average mass of the peptide or protein at a given isotopic abundance, such as natural abundance.In some instances, the mass of a peptide can be biased, for example, by isotopically labeling one or more amino acids in the peptide or protein.For each single peptide, some variation is expected around the average mass of the peptide, based on the exact isotopic composition of the peptide.The mass of a particular peptide can be determined by those skilled in the art.
[0049] A "vector," as used herein, refers to a recombinant plasmid or virus containing a nucleic acid that is delivered to a host cell either in vitro or in vivo.
[0050] The term "polynucleotide" or "nucleic acid" as used herein refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, the term includes, but is not limited to, single-stranded, double-stranded, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. The backbone of a nucleic acid can contain sugars and phosphate groups (as typically found in RNA or DNA), or modified or substituted sugar or phosphate groups.
[0051] Alternatively, the backbone of the nucleic acid may comprise a polymer of synthetic subunits such as phosphoramidates, and thus may be a mixture of oligodeoxynucleoside phosphoramidates (P-NH2) or phosphoramidate-phosphodiester oligomers. In addition, double-stranded nucleic acids can be obtained from single-stranded polynucleotide products of chemical synthesis by synthesizing a complementary strand and annealing the strands under appropriate conditions, or by synthesizing the complementary strand de novo using DNA polymerase with an appropriate primer.
[0052] A "recombinant viral vector" refers to a recombinant polynucleotide vector that contains one or more heterologous sequences (ie, a nucleic acid sequence that is not of viral origin).
[0053] "Recombinant AAV vector (rAAV vector)" refers to a polynucleotide vector that contains one or more heterologous sequences (i.e., nucleic acid sequences not of AAV origin), which may be flanked by at least one, e.g., two, AAV inverted terminal repeats (ITRs). Such rAAV vectors are replicated and packaged into infectious viral particles when present in a host cell that is infected with a suitable helper virus (or expresses suitable helper functions) and expresses the AAV rep and cap gene products (i.e., AAV Rep and Cap proteins).
[0054] "Virus particle" refers to a virus particle that is composed of at least one viral capsid protein and an encapsulated viral genome.
[0055] "Heterologous" means derived from a genotypically different entity than the rest of the entity to which it is compared or introduced or incorporated. For example, a nucleic acid introduced into a different cell type by genetic engineering techniques is a heterologous nucleic acid (and may encode a heterologous polypeptide when expressed). Similarly, a cellular sequence (e.g., a gene or portion thereof) incorporated into a viral vector is a heterologous nucleotide sequence relative to that vector.
[0056] "Inverted terminal repeat" or "ITR" sequences are relatively short sequences found at the ends of the viral genome and are arranged in an inverted manner. The "AAV inverted terminal repeat (ITR)" sequence is an approximately 145 nucleotide sequence present at both ends of the single-stranded AAV genome.
[0057] The term "hydrophilic interaction chromatography" or HILIC is intended to include processes that employ a hydrophilic stationary phase and a hydrophobic organic mobile phase, in which hydrophilic compounds are retained longer than hydrophobic compounds. In certain embodiments, the process utilizes a mobile phase of a water-miscible solvent.
[0058] The term "sample", as used herein, refers to a mixture of molecules, including at least viral particles, such as AAV particles, that is subjected to manipulation according to the methods of the invention, including, for example, separating, analyzing, extracting, concentrating, profiling, etc.
[0059] The term "chromatographic surface" as used herein includes a surface that is exposed to a sample or analyte. Chromatographic surfaces may be chemically modified, functionalized or activated, or may have a microstructure, e.g., pores. In certain embodiments, chromatographic surfaces may be hydrophobic, hydrophilic (polar), or ionic. In other embodiments, chromatographic surfaces are fully porous, superficially porous, or non-porous.
[0060] The term "chromatographic core" as used herein includes, but is not limited to, chromatographic materials comprising organic materials such as silica in the form of particles, monoliths, or another suitable structure, forming the inner portion of the material of the invention. In certain embodiments, the surface of the chromatographic core represents a chromatographic surface, or represents a material enveloped by a chromatographic surface, as defined herein. The chromatographic surface material may be disposed on the chromatographic core in a manner that allows for discernible discrete or distinct changes, or may be bonded to the chromatographic core in a manner that allows for a gradation of material and does not result in discontinuities on the inner core surface. In certain embodiments, the chromatographic surface material may be the same or different from the material of the chromatographic core, and may exhibit different physical or physiochemical properties from the chromatographic core, such as, but not limited to, pore volume, surface area, average pore size, carbon content, or hydrolytic pH stability.
[0061] The term "hydrophilic" as used herein describes having an affinity for water and attracting, adsorbing, or absorbing water.
[0062] The term "hydrophobic" as used herein describes having no affinity for water, repelling water, or not adsorbing or absorbing water.
[0063] "Chromatography" as used herein refers to the process of separating a mixture, for example a mixture containing a viral capsid protein. This involves passing the mixture through a stationary phase, which separates the molecules of interest in the mixture from other molecules, allowing one or more molecules of interest to be isolated. One example of a method of chromatographic separation is hydrophilic interaction liquid chromatography (HILIC).
[0064] "Contacting," as used herein, includes bringing together at least two substances in solution or in a solid phase, e.g., contacting the stationary phase of a chromatographic material with a sample, such as a sample containing virus particles.
[0065] overview Pompe disease is an autosomal recessive lysosomal storage disorder caused by mutations in the GAA gene, which encodes the lysosomal enzyme acid alpha-glucosidase (GAA), involved in the hydrolysis of glycogen to glucose. Deficiency of GAA leads to accumulation of glycogen in lysosomes with subsequent cell damage in cardiac, skeletal, and smooth muscles, and the central nervous system. Pompe disease can present early in life as infantile-onset Pompe disease (IOPD) or later in childhood to adulthood as late-onset Pompe disease (LOPD). In both types of Pompe disease, respiratory failure is the main cause of death.
[0066] Currently, the only U.S. Food and Drug Administration-approved treatment for Pompe disease is enzyme replacement therapy (ERT). However, systemically administered GAA does not cross the blood-brain barrier and therefore cannot treat CNS pathology and affected respiratory motor neurons. Furthermore, ERT only partially improves skeletal muscle abnormalities due to poor uptake into muscle fibers. As a result, two-thirds of patients with IOPD eventually require ventilator support, and patients with LOPD have persistent respiratory insufficiency.
[0067] Since Pompe disease is a monogenic disorder, gene therapy using adeno-associated virus (AAV) vectors is ideal. One strategy being investigated is the combination of enzyme replacement and binding antibodies. In one example, high expression of anti-CD63::GAA from the liver via gene therapy has been developed to overcome the immune response to the replacement enzyme observed in patients who do not have the endogenous enzyme (see Figure 1). As with all viral vector systems, it is important to ensure that the therapeutic composition contains the appropriate amount of correctly formed viral particles. Therefore, it is very important to determine the stoichiometry and protein composition of the viral particles.
[0068] An aspect of the present disclosure relates to a method for determining the stoichiometry of the protein components of the viral capsid of a viral particle. In an embodiment, the method includes subjecting a sample of viral particles to hydrophilic interaction liquid chromatography (HILIC) to separate the protein components of the viral capsid of a viral particle, such as a viral particle of interest for which information about the capsid is desired. In an embodiment, a HILIC column is contacted with the sample containing the viral particles. In certain embodiments, the method includes determining the mass of the protein components of the viral capsid to identify the protein components separated by HILIC, for example, using mass spectrometry techniques such as those described herein. In an embodiment, the method includes calculating the relative abundance of the protein components of the viral capsid from the HILIC separation, for example, by using ultraviolet (UV) detection of the protein components of the viral capsid eluted from the HILIC column to determine the stoichiometry of the protein components of the viral capsid of the viral particle. For example, UV peak areas can be used to determine the relative abundance of capsid proteins and calculate the stoichiometry of capsid proteins of a biological capsid (see FIG. 4). In another example, peak height and / or peak UV intensity are used to determine relative abundance. In some embodiments, the retention time of different proteins on the HILIC column is determined as a function of the mobile phase used, and in subsequent analyses, this retention time can be used to determine the relative abundance of proteins and proteins from the viral particles, e.g., to generate a standard value(s), without the need to determine the mass and / or identity of the protein each time a stoichiometry determination is made. Prior to the present disclosure, it was extremely difficult to resolve different capsid proteins using traditional chromatographic techniques (see Figures 3A and 3B). Using the sample conditions described herein for HILIC, good separation of AAV viral particles was achieved. In addition, the use of a HILIC column eliminates any requirement for a denaturation step. In certain embodiments, the method is used to determine the serotype of the viral particles.For example, the masses of VP1, VP2 and VP3 of each AAV serotype are unique and can be used to identify or differentiate AAV capsid serotypes. In addition, the separated capsid proteins can be subjected to downstream analyses, such as, for example, accurate mass measurements at the intact protein level, as well as determination of the protein sequence and post-translational modifications of the capsid proteins.
[0069] An aspect of the present disclosure relates to a method for determining heterogeneity of protein components in a capsid of a virus particle. In an embodiment, the method includes subjecting the virus particle to HILIC to separate protein components of the virus particle capsid. In an embodiment, the method includes determining the mass of the protein components of the protein capsid. In some cases, the mass of the protein components of the virus particle capsid is compared to the theoretical mass of the virus particle capsid. Deviations in one or more of the masses of the protein components of the virus particle capsid indicate that one or more proteins of the capsid are heterogeneous (see FIG. 5A). Conversely, the absence of deviations indicates that the proteins of the capsid are homogeneous (see FIGS. 5B-5D). In an embodiment, the heterogeneity is due to one or more of serotype mixing, variant capsids, substitutions of capsid amino acids, truncated capsids, or modified capsids. In some embodiments, the determination of the stoichiometry of the protein components of the viral capsid of the viral particle and the determination of the heterogeneity of the protein components in the capsid of the viral particle are performed on the same sample, e.g., in a single test.
[0070] In certain embodiments, the viral particles are adeno-associated virus (AAV) particles, and the disclosed methods can be used to determine the stoichiometry of protein components in the capsid of the AAV particle and / or the heterogeneity of protein components in the capsid of the AAV particle. In embodiments, the protein components of the protein capsid include VP1, VP2, and VP3 of the AAV particle. In embodiments, the AAV particle is a recombinant AAV (rAAV) particle. In embodiments, the AAV particle includes an AAV vector encoding a heterologous transgene. In some embodiments, the determined or calculated masses of the present disclosure (e.g., determined or calculated masses of VP1, VP2, and / or VP3 of the AAV particle) can be compared to a reference, e.g., theoretical masses of VP1, VP2, and / or VP3 of one or more AAV serotypes (see, e.g., Figures 2A and 2B). The reference can include theoretical masses of one or more VP1, VP2, and / or VP3 of any of the AAV serotypes. For example, in some embodiments, the mass of VP1, VP2, and / or VP3 is compared to the theoretical mass of one or more of an AAV1 capsid, an AAV2 capsid, an AAV3 capsid, an AAV4 capsid, an AAV5 capsid, an AAV6 capsid, an AAV7 capsid, an AAV8 capsid, an AAVrh8 capsid, an AAV9 capsid, an AAV10 capsid, an AAV11 capsid, an AAV12 capsid, or variants thereof. In some embodiments, the determined or calculated mass (e.g., the determined or calculated mass of VP1, VP2, and / or VP3 of an AAV particle) can be compared to the theoretical mass of VP1, VP2, and / or VP3 of the corresponding AAV serotype.
[0071] In some embodiments, the methods of the present disclosure may include determining the protein heterogeneity of the AAV particle. In some embodiments, deviations in one or more of the masses of VP1, VP2, and / or VP3 (e.g., deviations from a reference mass, such as a theoretical mass, a predicted mass, or a predicted mass) indicate heterogeneity of the AAV capsid proteins. In some embodiments, heterogeneity may include, but is not limited to, one or more of the following: a mixture of serotypes, a variant capsid, a substitution of capsid amino acids, a truncated capsid, or a modified capsid.
[0072] In some embodiments, a method for determining AAV particle heterogeneity may include subjecting denatured AAV particles to LC / MS (e.g., as described herein), determining the masses of VP1, VP2, and VP3 of the AAV particles, and comparing these masses to the theoretical masses of VP1, VP2, and VP3 of the AAV serotype, and further subjecting fragments of VP1, VP2, and / or VP3 to LC / MS / MS, determining the masses of fragments of VP1, VP2, and VP3 of the AAV particles, and comparing these masses to the theoretical masses of VP1, VP2, and VP3 of the AAV serotype (a deviation in one or more of the masses of VP1, VP2, or VP3 indicates AAV capsid heterogeneity).
[0073] In embodiments, the AAV particle comprises an AAV1 capsid, an AAV2 capsid, an AAV3 capsid, an AAV4 capsid, an AAV5 capsid, an AAV6 capsid, an AAV7 capsid, an AAV8 capsid, an AAVrh8 capsid, an AAV9 capsid, an AAV10 capsid, an AAV11 capsid, an AAV12 capsid, or a variant thereof.
[0074] In embodiments, the masses of VP1, VP2, and VP3 are compared to the theoretical mass of one or more of an AAV1 capsid, an AAV2 capsid, an AAV3 capsid, an AAV4 capsid, an AAV5 capsid, an AAV6 capsid, an AAV7 capsid, an AAV8 capsid, an AAVrh8 capsid, an AAV9 capsid, an AAV10 capsid, an AAV11 capsid, an AAV12 capsid, or a variant thereof.
[0075] In embodiments, the AAV particle includes an AAV1 ITR, an AAV2 ITR, an AAV3 ITR, an AAV4 ITR, an AAV5 ITR, an AAV6 ITR, an AAV7 ITR, an AAV8 ITR, an AAVrh8 ITR, an AAV9 ITR, an AAV10 ITR, an AAV11 ITR, or an AAV12 ITR.
[0076] In embodiments, the AAV particles have a capsid serotype selected for transducing cells of the liver of a subject. In embodiments, the AAV particles have capsid serotypes AAV7, AAV8, or AAV9 that are selective for transducing cells of the liver of a subject.
[0077] In some embodiments, the AAV particle is a recombinant AAV (rAAV) particle. In some embodiments, the AAV particle comprises an AAV vector encoding a heterologous transgene. In some embodiments, the AAV particle has capsid serotype AAV7, AAV8, or AAV9. In some embodiments, the AAV particle has capsid serotype AAV9. In some embodiments, the AAV particle has capsid serotype AAV9 and is a viral vector encoding lysosomal alpha glucosidase (GAA) linked to an antibody specific for an antigen expressed from muscle cells (e.g., an anti-CD63 antibody).
[0078] While AAV is the model viral particle of the present disclosure, it is contemplated that the methods of the present disclosure can be applied to a variety of viral profiles, e.g., viral families, subfamilies, and genera. The methods of the present disclosure can find use, for example, in profiling VPs to monitor VP expression, post-translational modification, and cleavage, as well as to ensure product consistency during VLP manufacturing, confirm site-directed mutagenesis or structural characterization for capsid protein engineering applications, and / or monitor or detect heterogeneity of viral particles or preparations.
[0079] In embodiments, the viral vector encodes a heterologous transgene.
[0080] In embodiments, the viral particle belongs to a virus family selected from the group consisting of adenovirus, parvovirus, retrovirus, baculovirus, and herpesvirus.
[0081] In embodiments, the viral particle belongs to a viral genus selected from the group consisting of atadenovirus, aviadenovirus, ictadenovirus, mastadenovirus, siaadenovirus, ambidensovirus, brevidensovirus, hepandensovirus, iteradensovirus, penstildensovirus, amdoparvovirus, abeparvovirus, bocaparvovirus, copiparvovirus, dependoparvovirus, erythroparvovirus, protoparvovirus, tetraparvovirus, alpharetrovirus, betaretrovirus, deltaretrovirus, epsilonretrovirus, gammaretrovirus, lentivirus, spumavirus, alphabaculovirus, betabaculovirus, deltabaculovirus, gammabaculovirus, irtovirus, mardivirus, simplexvirus, varicellovirus, cytomegalovirus, muromegalovirus, proboscivirus, roseolovirus, lymphocryptovirus, macavirus, percavirus, and rhadinovirus.
[0082] In embodiments, the retrovirus is Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), mouse mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend virus, murine stem cell virus (MSCV), Rous sarcoma virus (RSV), human T-cell leukemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), equine immunodeficiency virus (EIV), Visna-Maedi virus; caprine arthritis-encephalitis virus; equine infectious anemia virus; feline immunodeficiency virus (FIV); bovine immunodeficiency virus (BIV); or simian immunodeficiency virus (SIV).
[0083] Hydrophilic interaction chromatography (HILIC) is a type of NP-HPLC that can be performed with a partially aqueous mobile phase, allowing normal-phase separation of peptides, carbohydrates, nucleic acids, and many proteins. The elution order in HILIC is the opposite of that in reversed-phase HPLC, from least polar to most polar.
[0084] HILIC separates analytes based on polar interactions between the analytes and the stationary phase (e.g., the substrate). Polar analytes associate with and are retained by the polar stationary phase. The strength of adsorption is greater for more polar analytes, and interactions between polar analytes and the polar stationary phase (relative to the mobile phase) result in longer elution times. The use of more polar solvents in the mobile phase tends to result in shorter retention times for analytes, whereas the use of more hydrophobic solvents tends to result in longer retention times.
[0085] HILIC can use a wide variety of matrices, including those used for column chromatography, including silica, amino, amide, cellulose, cyclodextrin and polystyrene matrices. For example, examples of useful substrates that can be used in column chromatography include polysulfoethyl aspartamide (e.g., manufactured by PolyLC), sulfobetaine substrates such as ZIC (registered trademark)-HILIC (e.g., manufactured by SeQuant), POROS (registered trademark) HS (e.g., manufactured by Applied Biosystems), POROS (registered trademark) S (e.g., manufactured by Applied Biosystems), polyhydroethyl aspartamide (e.g., manufactured by PolyLC), Zorbax 300 SCX (e.g., manufactured by Agilent), PolyGLYCOPLEX (registered trademark) (e.g., manufactured by PolyLC), Amide-80 (e.g., manufactured by Tosohaas), TSK GEL (registered trademark) Amide-80 (e.g., manufactured by Tosohaas), polyhydroxyethyl A (e.g., manufactured by PolyLC), Glyco-Sep-N (e.g., manufactured by Oxford GlycoSciences), and Atlantis HILIC (e.g., manufactured by Waters). Columns that can be used in the disclosed methods include columns that utilize one or more of the following functional groups: carbamoyl groups, sulfopropyl groups, sulfoethyl groups (e.g., poly(2-sulfoethylaspartamide)), hydroxyethyl groups (e.g., poly(2-hydroxyethylaspartamide)), and aromatic sulfonic acid groups.
[0086] In certain embodiments, the capsid proteins are separated on a HILIC column, and then purified and / or separated from the sample by eluting from the HILIC column and resolving the individual capsid proteins using, for example, a mobile phase gradient. In certain instances, the capsid proteins eluted from the HILIC column are separated into one or more fractions. Such fractions can be used for subsequent analysis, such as MS analysis. In certain embodiments, the method includes identifying the capsid proteins present in one or more of the fractions.
[0087] The mobile phase used may include buffers, e.g., acetonitrile and water, with or without ion-pairing reagents. Ion-pairing reagents include formates, acetates, TFA and salts. A gradient of buffers may be used, e.g., when two buffers are used, the concentration or percentage of the first buffer may be decreased while the concentration or percentage of the second buffer may be increased during the chromatographic run. For example, the percentage of the first buffer may be decreased from about 100% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 50%, about 45%, or about 40% to about 0%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, or about 40% during the chromatographic run. As another example, the percentage of the second buffer may increase during the run from about 0% to about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, or about 40% to about 100%, about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 50%, about 45%, or about 40%. In an embodiment, the percentage of mobile phase A in the chromatography increases over time. Optionally, the concentrations or percentages of the first and second buffers may be returned to starting values at the end of the chromatography run. As an example, the percentage of the first buffer may change in five steps from 85% to 63%, 59%, 10%, and 85%, and the percentage of the second buffer in the same steps may change from 15% to 37%, 41%, 90%, and 15%. The ratios may be changed stepwise in a linear gradient or may be changed non-linearly (e.g., stepwise). For example, the gradient may be multiphasic, e.g., biphasic, triphasic, etc. In a preferred embodiment, the methods described herein use a gradient of decreasing acetonitrile buffer with corresponding increase in the polarity of the mobile phase without the use of ion-pairing reagents. In an embodiment, HILIC uses a mobile phase A comprising trifluoroacetic acid in water. In an embodiment, mobile phase A comprises about 0.1% trifluoroacetic acid. In an embodiment, the chromatography comprises a mobile phase B comprising trifluoroacetic acid in acetonitrile.In an embodiment, mobile phase B contains about 0.1% trifluoroacetic acid.
[0088] The column temperature can be maintained constant throughout the chromatography run, for example, using a commercially available column heater. In some embodiments, the column is maintained at a temperature of about 50°C to about 70°C, for example, about 50°C to about 60°C, about 55°C to about 60°C, for example, about 50°C, about 55°C, about 60°C, about 65°C, or about 70°C. In one embodiment, the temperature is about 60°C.
[0089] The flow rate of the mobile phase can be between about 0 and about 100 ml / min. For analytical purposes, the flow rate typically ranges from 0 to 10 ml / min, and for preparative HPLC, flow rates above 100 ml / min can be used. For example, the flow rate can be about 0.5, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, or about 5 ml / min. When substituting a column of the same length with the same packing but smaller diameter, the flow rate must be reduced to maintain the same peak retention times and peak resolution observed in the larger diameter column. Preferably, a flow rate equivalent to about 1 ml / min in a 4.6×100 mm, 5 μm column is used.
[0090] Run times can be between about 15 and about 240 minutes, e.g., about 20 to about 70 minutes, about 30 to about 60 minutes, about 40 to about 90 minutes, about 50 to about 100 minutes, about 60 to about 120 minutes, about 50 to about 80 minutes. In embodiments, mobile phase A is ramped from about 15% to about 100% over about 45 minutes.
[0091] In some embodiments, the method includes subjecting the virus particles to liquid chromatography / mass spectrometry (LC / MS). As known in the art, LC / MS utilizes liquid chromatography to physically separate ions and mass spectrometry to generate mass spectral data from the ions. Such mass spectral data can be used to determine the identity of the particles, for example, by molecular weight or structure, mass, amount, purity, etc. These data can represent properties of the detected ions, for example, signal intensity (e.g., abundance) over time (e.g., retention time), or relative abundance relative to mass-to-charge ratio.
[0092] In some embodiments, mass spectrometry (e.g., as used in LC / MS as described herein) may refer to electrospray ionization mass spectrometry (ESI-MS). ESI-MS is known in the art as a technique for analyzing ions obtained from a solution using electrical energy by the use of mass spectrometry (see, e.g., Yamashita, M. and Fenn, JB (1984). Phys. Chem. 88:4451-4459). Ionic species (or neutral species that are ionized in solution or in the gas phase) are dispersed into an aerosol of charged droplets as the solution passes through a small capillary that has a voltage relative to ground (e.g., the surrounding chamber walls), and subsequently move from the solution to the gas phase by evaporation of the solvent, reducing the size of the charged droplets and releasing the sample ions from the charged droplets. ESI is performed by mixing the sample with a volatile acid and an organic solvent and injecting it through a conductive needle that is applied with a high voltage. The charged droplets sprayed (or ejected) from the tip of the needle are introduced directly into the mass spectrometer and dried by heat and vacuum as they fly. Once the droplets have dried, the remaining charged molecules are directed by an electromagnetic lens to a mass detector for mass analysis. In one embodiment, the eluted sample is directly introduced from the capillary into the electrospray nozzle, e.g., the capillary acts as the sample loader. In another embodiment, the capillary itself acts as both the extractor and the electrospray nozzle.
[0093] In MALDI, analyte molecules (e.g., proteins) are deposited on a metal target and co-crystallized with an organic matrix. The sample is dried and inserted into a mass spectrometer and analyzed, typically by time-of-flight (TOF) detection. In one embodiment, the eluted sample is directly deposited onto the metal target from the capillary, e.g., the capillary itself acts as the sample loader. In one embodiment, the extracted analyte is deposited on a MALDI target, a MALDI ionization matrix is added, and the sample is ionized and analyzed, e.g., by TOF detection.
[0094] In some embodiments, other ionization modes are used, such as ESI-MS, turbospray ionization mass spectrometry, nanospray ionization mass spectrometry, thermospray ionization mass spectrometry, sonic spray ionization mass spectrometry, SELDI-MS, and MALDI-MS. In general, the advantage of these methods is that they allow for "just-in-time" purification of the sample and direct introduction into the ionization environment. It is important to note that the various ionization and detection modes impose their own constraints on the nature of the desorption solution used, and it is important that the desorption solution is compatible with both. For example, in many applications, the sample matrix must have low ionic strength or be within a certain pH range, etc. In ESI, salts in the sample may impede detection by reducing ionization or clogging the nozzle. This problem is addressed by presenting the analyte with low salt and / or by using volatile salts. In the case of MALDI, the analyte must be in a solvent that is compatible with the spotting on the target and the ionization matrix employed.
[0095] In some embodiments, the method includes subjecting the viral particles of the present disclosure to liquid chromatography / mass spectrometry-mass spectrometry (LC / MS / MS) or subjecting digested fragments of the denatured viral particles of the present disclosure to LC / MS / MS. As known in the art, LC / MS / MS (the term "liquid chromatography-tandem mass spectrometry" may be used interchangeably herein) utilizes liquid chromatography to physically separate ions and mass spectrometry to generate mass spectral data from the ions, where the mass spectrometry uses multiple stages of mass (e.g., m / z) separation, typically separated by a fragmentation step. For example, ions of interest within a range of m / z may be separated and fragmented in a first MS, and then further separated based on their individual m / z in a second MS. Ion fragmentation may include techniques such as, but not limited to, collision-induced dissociation (CID), high-energy collision dissociation (HCD), electron capture dissociation (ECD), or electron transfer dissociation (ETD).
[0096] A variety of mass spectrometers suitable for LC / MS and / or LC / MS / MS are known in the art, including, but not limited to, time-of-flight (TOF) analyzers, quadrupole mass filters, quadrupole TOF (QTOF), and ion traps (e.g., Fourier transform mass spectrometers or Orbitraps). In an Orbitrap, a barrel-shaped outer electrode at ground potential and a spindle-shaped central electrode are used to trap ions in orbits that rotate elliptically around the central electrode while being confined by a balance of centrifugal and electrostatic forces and oscillate along a central axis. The use of such instruments employs a Fourier transform operation to convert the time domain signal (e.g., frequency) from the detection of the image current into a high-resolution mass measurement (e.g., nanoLC / MS / MS). Further descriptions and details can be found, for example, in Scheltema, RA et al. (2014) Mol. Cell Proteomics 13:3698-3708; Perry, RH et al. (2008) Mass. Spectrom. Rev. 27:661-699; and Scigelova, M. et al. (2011) Mo / . Cell Proteomics 10:M11 1.009431.
[0097] In some embodiments, the mass of a viral capsid protein can be determined, for example, based on LC / MS data and / or LC / MS / MS data. In some embodiments, the mass of VP1, VP2 and VP3 of an AAV particle, or the mass of a fragment of VP1, VP2 and VP3 of an AAV particle, can be determined, for example, based on LC / MS data and / or LC / MS / MS data. A variety of methods are known in the art for determining the mass and / or identity of a protein from MS data. For example, peptide mass fingerprinting can be used to determine a protein sequence based on MS data, or a protein can be identified based on MS / MS data for one or more constituent peptides. When using tandem MS, product ion scanning can be used to analyze the m / z data for one or more peptides of a protein of interest. Software known in the art can then be used, for example, to match the identified peaks to reference or known peaks, or to group the peaks into isotopomer envelopes. The peptide mass values can be compared to a database of known peptide sequences. For example, Mascot can be used to match observed peptides to theoretical database peptides that arise, for example, from applying a particular digestion pattern to an in silico protein database. Other suitable software can include, but are not limited to, Proteome Discoverer, ProteinProspector, X! Tandem, Pepfinder, Bonics, or MassLynx™ (Waters).
[0098] In some embodiments, the heterologous nucleic acid is operably linked to a promoter. Exemplary promoters include the cytomegalovirus (CMV) immediate early promoter, the RSV LTR, the MoMLV LTR, the phosphoglycerate kinase-1 (PGK) promoter, the simian virus 40 (SV40) promoter and the CK6 promoter, the transthyretin promoter (TTR), the TK promoter, the tetracycline responsive promoter (TRE), the HBV promoter, the hAAT promoter, the LSP promoter, the chimeric liver specific promoter (LSP), the E2F promoter, the telomerase (hTERT) promoter; the cytomegalovirus enhancer / chicken beta-actin / rabbit beta-globin promoter (CAG promoter; Niwa et al., Gene, 1991, 108(2):193-9) and the elongation factor 1-alpha promoter (EF1-alpha) promoter (Kim et al., Gene, 1990, 91(2):217-23 and Guo et al., Gene Ther., 1996, 3(9):802- 10). In some embodiments, the promoter comprises a cytomegalovirus enhancer linked to a human β-glucuronidase promoter or a chicken β-actin (CBA) promoter. The promoter can be a constitutive, inducible or repressible promoter. In some embodiments, the present invention provides a recombinant vector comprising a nucleic acid encoding a heterologous transgene of the present disclosure operably linked to a CBA promoter.
[0099] Examples of constitutive promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer), the SV40 promoter, the dihydrofolate reductase promoter, the 13-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EFla promoter.
[0100] Inducible promoters allow for the regulation of gene expression and can be regulated by exogenously supplied compounds, environmental factors such as temperature, or the presence of certain physiological conditions, such as acute phase, a particular differentiation state of cells, or only in replicating cells. Inducible promoters and induction systems are available from a variety of commercial sources, including but not limited to Invitrogen, Clontech, and Ariad. Many other systems have been described and can be readily selected by one of skill in the art. Examples of inducible promoters regulated by an exogenously supplied promoter include the zinc-inducible sheep metallothionine (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (WO98 / 10088); the ecdysone insect promoter (No et al., Proc. Natl. Acad. Sci. USA, 93:3346-3351 (1996)), the tetracycline repressible system (Gossen et al., Proc. Natl. Acad. Sci. USA, 89:5547-5551 (1992)), the tetracycline inducible system (Gossen et al., Science, 268:1766-1769 (1995), Harvey et al., Science, 268:1766-1769 (1995), and the ecdysone insect promoter (No et al., Proc. Natl. Acad. Sci. USA, 93:3346-3351 (1996)). al., Curr. Opin. Chem. Biol., 2:512-518 (1998)), the RU486-inducible system (Wang et al., Nat. Biotech., 15:239-243 (1997) and Wang et al., Gene Ther., 4:432-441 (1997)) and the rapamycin-inducible system (Magari et al., J. Clin. Invest., 100:2865-2872 (1997)). Other types of inducible promoters that may also be useful in the present context include those that are regulated by specific physiological conditions, such as temperature, acute phase, a specific differentiation state of the cell, or only in replicating cells.
[0101] In another embodiment, the native promoter or a fragment thereof is used for the transgene. The native promoter can be used when it is desired that the expression of the transgene should reproduce the natural expression. The native promoter can be used when the expression of the transgene must be regulated temporally or developmentally, or tissue-specifically, or in response to a specific transcriptional stimulus. In a further embodiment, other native expression control elements, such as enhancer elements, polyadenylation sites, or Kozak consensus sequences, can also be used to reproduce the natural expression.
[0102] In some embodiments, the regulatory sequence confers tissue-specific gene expression. In some cases, the tissue-specific regulatory sequence binds to a tissue-specific transcription factor that induces transcription in a tissue-specific manner. Such tissue-specific regulatory sequences (e.g., promoters, enhancers, etc.) are well known in the art.
[0103] In some embodiments, the vector comprises an intron. For example, in some embodiments, the intron is a chimeric intron derived from chicken beta-actin and rabbit beta-globin. In some embodiments, the intron is a minute virus of mice (MVM) intron.
[0104] In some embodiments, the vector comprises a polyadenylation (polyA) sequence, of which many are known in the art, including the bovine growth hormone (BGH) Poly(A) sequence (see, e.g., Accession No. EF592533), the SV40 polyadenylation sequence, and the HSV TK pA polyadenylation sequence.
[0105] The example systems, methods, and acts described in the foregoing embodiments are illustrative, and in alternative embodiments, certain acts may be performed in a different order, in parallel with one another, omitted entirely, and / or combined between different example embodiments, and / or certain additional acts may be performed, without departing from the scope and spirit of the various embodiments. Accordingly, such alternative embodiments are included in the examples described herein.
[0106] Although specific embodiments have been described in detail above, the description is for illustrative purposes only. Therefore, it is understood that many of the above aspects are not intended to be necessary or essential elements unless otherwise specified. Modifications of the disclosed aspects of the exemplary embodiments and their corresponding equivalent elements or acts, in addition to those described above, can be made by those skilled in the art who have the benefit of this disclosure without departing from the spirit and scope of the embodiments defined in the following claims, and the scope shall be given the broadest interpretation so as to include such modifications and equivalent structures.
[0107] The following examples are provided to illustrate certain features of certain embodiments, however the specific features described below should not be construed as limiting the scope of the invention, and those skilled in the art will recognize equivalents from the examples. EXAMPLES
[0108] The following examples are presented to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods of the present invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight unless otherwise indicated, temperature is in degrees Celsius, room temperature is about 25°C, and pressure is at or near atmospheric pressure.
[0109] Isolation of capsid proteins from intact AAV particles To separate intact AAV9 viral particles, 1 μL of the AAV sample was injected onto the HILIC column described in the table below. The results of the separation are shown in Figure 4. As shown, the three AAV capsid proteins showed complete degradation from each other.
[0110] Table 1 outlines the chromatographic conditions used to separate AAV9 capsid proteins from intact AAV9 capsids.
[0111] Table 1. Summary of chromatographic conditions TIFF0007577719000001.tif71149
[0112] Compared to RP-based separations, the unique retention mechanism of the HILIC column worked surprisingly well for VP separations (see Figures 4, 3A and 3B).
[0113] Mass spectrometry analysis of isolated AAV capsid proteins One advantage of the method described herein is that no sample preparation is required. 1 uL of sample was directly injected into the LC-MS and the resulting data was analyzed. For intact mass analysis, the following tune parameters were applied to the Q-Exactive Plus mass spectrometer: TIFF0007577719000002.tif49128
[0114] 5A-5D show mass spectra of individual capsid proteins. As shown in FIG 5A, VP3 had protein heterogeneity.
[0115] As shown in Figure 6, the peak heights can be used to determine the stoichiometry of intact AAV particles.
[0116] The present invention is not limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to be within the scope of the appended claims.
Claims
1. 1. A method for isolating protein components of intact, non-enveloped virus particles, comprising: obtaining a sample containing said virus particles; and subjecting the sample to hydrophilic interaction liquid chromatography (HILIC) to separate protein components of the viral capsid of the viral particles, including adeno-associated viral (AAV) particles; The method comprising:
2. The method described in claim 1, wherein the protein components of the viral capsid include VP1, VP2 and VP3 of the AAV particle.
3. 3. The method of claim 2, wherein the AAV particles comprise an AAV1 capsid, an AAV2 capsid, an AAV3 capsid, an AAV4 capsid, an AAV5 capsid, an AAV6 capsid, an AAV7 capsid, an AAV8 capsid, an AAVrh8 capsid, an AAV9 capsid, an AAV10 capsid, an AAV11 capsid, an AAV12 capsid, or a variant thereof.
4. 3. The method of claim 2, wherein the AAV particle is a recombinant AAV (rAAV) particle or an AAV vector encoding a heterologous transgene.
5. 5. The method of claim 4, wherein the heterologous transgene is operably linked to a promoter selected from the group consisting of an inducible promoter, a cytomegalovirus (CMV) promoter, a Rous sarcoma virus (RSV) LTR, a Moloney murine leukemia virus (MoMLV) LTR, a phosphoglycerate kinase-1 (PGK) promoter, a simian virus 40 (SV40) promoter, a CK6 promoter, a transthyretin (TTR) promoter, a thymidine kinase (TK) promoter, a tetracycline-responsive (TRE) promoter, a hepatitis B virus (HBV) promoter, a human alpha 1 antitrypsin (hAAT) promoter, a light chain promoter (LSP), an E2 factor (E2F) promoter, a telomerase (hTERT) promoter, a cytomegalovirus enhancer / chicken beta-actin / rabbit beta-globin (CAG) promoter, and an elongation factor 1-alpha (EF-1α) promoter.
6. The method of claim 2, wherein the AAV particles have a capsid serotype selected for transducing cells of the subject's liver.
7. The method of claim 2, wherein the AAV particle is a viral vector having the capsid serotype AAV9 and encoding lysosomal alpha glucosidase (GAA) linked to an anti-CD63 antibody.
8. 2. The method of claim 1, wherein the viral particle belongs to a virus family selected from the group consisting of Adenoviridae, Parvoviridae, Retroviridae, Baculoviruses, and Herpesviridae.
9. 9. The method of claim 8, wherein the retrovirus is Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), mouse mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend virus, murine stem cell virus (MSCV), Rous sarcoma virus (RSV), human T-cell leukemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), equine immunodeficiency virus (EIV), Visna-Maedi virus; Caprine arthritis-encephalitis virus; Equine infectious anemia virus; Feline immunodeficiency virus (FIV); Bovine immunodeficiency virus (BIV); or Simian immunodeficiency virus (SIV).
10. 2. The method of claim 1, wherein the HILIC uses a mobile phase A comprising trifluoroacetic acid in water, the concentration of the trifluoroacetic acid being about 0.1%.
11. 2. The method of claim 1, wherein the HILIC uses a mobile phase B comprising trifluoroacetic acid in acetonitrile, the concentration of the trifluoroacetic acid being about 0.1%.
12. 11. The method of claim 10, wherein the percentage of mobile phase A is increased from about 15% to about 100% over about 45 minutes.
13. 11. The method of claim 10, wherein the proportion of mobile phase A increases over time, and the proportion of mobile phase A is then decreased to about its starting value.
14. 12. The method of claim 11, wherein the proportion of mobile phase B decreases over time, and the proportion of mobile phase B is then increased to about its starting value.
15. 2. The method of claim 1, wherein the flow rate of the mobile phase in the HILIC is from about 0.5 mL / min to about 5 mL / min, or the flow rate is about 1 mL / min.
16. 2. The method of claim 1, wherein subjecting the sample to HILIC comprises contacting the sample with a substrate selected from the group consisting of a silica substrate, an amino substrate, an amide substrate, a cellulose substrate, a cyclodextrin substrate, and a polystyrene substrate.
17. 10. The method of claim 1, further comprising collecting a plurality of fractions eluted from the HILIC step.
18. 18. The method of claim 17, wherein the viral particles comprise AAV particles and the multiple fractions comprise a fraction containing VP1, a fraction containing VP2, a fraction containing VP3, or a combination thereof.
19. The method of claim 1 , further comprising subjecting the separated protein components to mass spectrometry analysis.
20. 20. The method of claim 19, wherein the mass spectrometry analysis of the separated protein components is used to characterize protein expression levels, protein stoichiometry, post-translational modifications, truncations, site-directed mutagenesis, protein structure, protein heterogeneity, or a combination thereof.
Citation Information
Patent Citations
Polypeptide separation method
JP2014527518A
Detection Of Intact Recombinant Viruses
US20080113336A1
Gene therapy for treating mucopolysaccharidosis type i
WO2017136500A1
Methods for detecting aav
WO2018035059A1
